Idoxifene对人乳内动脉的舒张作用

为了研究idoxifene(吲哚昔酚,一种新型雌激素受体调节剂)对人乳内动脉(human internal mammarya artery,HIMA)的舒张作用及其机制,采用离体血管灌流的方法,观察idoxifene对完整内皮和去内皮HIMA的舒张作用,以及L-NAME和美蓝(metllylene blue,MB)对这一过程的影响,并且和17β雌二醇(17β-estradiol,E2)的舒血管作用进行了比较。实验中观察到保留血管内皮时idoxifenc(0．01～10μmol／L)和E2(0．1～100μmol／I,)可以剂量依赖性地舒张血管,且血管对idoxifene的灵敏度比对E2高15倍左右,而去内皮时则无此作用;NO合成酶阻断剂L-NAME和鸟苷酸环化酶(guanylate cyclasc,GC)的抑制剂MB使idoxifene舒张HIMA的作用完全消失。上述结果表明：idoxifene能够剂量依赖性地舒张HIMA,而且比E2更有效。idoxifene的这种作用是通过NO-GC-cGMP通路实现的。     

血管钠肽对大鼠肠系膜动脉平滑肌细胞Ca2+激活K+通道的作用

目的研究血管钠肽(VNP)对大鼠肠系膜动脉血管平滑肌细胞(VSMCs)Ca2+激活K+通道(Kca)的作用及其机制.方法采用全细胞膜片钳技术观察VNP对Kca的影响,以及HS-142-1、8-Br-cGMP和美蓝(MB)在这一过程中的作用.结果①VNP(10-6 mol/L)显著增强Kca(P＜0.05,n=5).②8-Br-CGMP(10-3mol/L)模拟VNP增强Kca的作用(P＜0.05,n=6).③HS-142-1(2×10-5mol/L)或MB(10-5mol/L)完全阻断VNP增加Kca电流密度的作用.结论VNP通过作用于VSMCs的钠尿肽GC耦联受体,升高细胞内的cGMP水平,激活Kca.     

血管钠肽抑制异丙肾上腺素增强的大鼠心肌细胞钙瞬变

采用光谱荧光法研究血管钠肽(vasonatrin peptide,VNP)对心肌细胞内钙瞬变的作用及其机制,观察钠尿肽鸟苷酸环化酶(guanylate cyclase,GC)受体的特异性阻断剂(HS-142-1)、8-溴-环磷酸鸟苷(8-Br-cGMP)和镁蓝(methylene blue,MB)对心肌细胞内钙瞬变的影响。结果显示,异丙肾上腺素(isoproterenol,Iso)(10~(-10)～10~(-6)mol/L)可剂量依赖性地引起心肌细胞内钙瞬变增强,相对于对照组分别增强(13±8)%(P>0.05)、(26±13)%(P<0.05)、(66±10)%(P<0.01)、(150±10)%(P<0.01)和(300±25)%(P<0.01)。此效应可被β肾上腺素受体阻断剂普萘洛尔(10~(-6)mol/L)所阻断。VNP(10~(-10)～10~(-6)mol/L)可剂量依赖性地抑制Iso(10~(-8)mol/L)引起的心肌细胞内钙瞬变幅值的升高,相对于Iso(10~(-8)mol/L)分别减弱(99±3)%(P>0.05)、(96±2)%(P<0.05)、(84±6)%(P<0.01)、(66±3)%(P<0.01)和(62±3)%(P<0.01)。8-Br-cGMP(10~(-7)～10~(-3)mol/L)也可剂量依赖性地抑制Iso(10~(-8)mol/L)引起心肌细胞内钙瞬变的增强。HS-142-1(2×10~(-5)mol/L)使VNP的作用几乎完全消失。MB是GC的抑制剂,10~(-5)mol/L MB不但使VNP的作用完全消失,而且增强Iso对心肌细胞内钙瞬变的效应。VNP和HS-142-1本身对心肌细胞内钙瞬变无显著影响。而MB使心     

大、小动脉内皮细胞乙酰胆碱作用靶标药理学特性的比较

目的 :比较大、小动脉内皮细胞乙酰胆碱作用靶标药理学特性的差异。方法 :采用大鼠尾动脉螺旋状血管条和主动脉离体血管环两种组织 ,对比观察乙酰胆碱 (ACh)诱发大、小动脉内皮依赖性舒张反应特征的差异 ,从而进一步研究小动脉内皮细胞乙酰胆碱作用靶标的药理学特性。结果 :氯化钾 (6 0mmol/L)预致血管收缩的尾动脉和主动脉对不同浓度ACh (10 -8～ 10 -4mol/L)产生内皮依赖性舒张反应 ,且呈剂量依赖性。L Nω 硝基精氨酸甲酯 (L NAME :10 -4mol/L)或美蓝 (MB :10 -5mol/L)与吲哚美辛 (Indo :10 -4mol/L)联用仅可部分地阻断ACh诱发尾动脉内皮依赖性舒张反应 ;而L NAME或MB可完全阻断ACh诱发主动脉内皮依赖性舒张反应。结论 :ACh激活大、小动脉上内皮细胞乙酰胆碱作用靶标诱发内皮依赖性舒张反应的药理学性质不同 ,在小动脉上 ,除了NO和PGI2介导外 ,还有一种非NO和非PGI2 的舒血管因子参与 ;在大动脉上 ,内皮依赖性舒张反应主要由NO介导     

美皂异黄酮非内皮依赖性血管舒张作用及其机制

目的:探讨植物雌激素美皂异黄酮舒张血管的可能机制。方法:采用MedLab生物信号采集系统记录灌流大鼠胸主动脉环张力变化。结果:美皂异黄酮(10-9~10-4mol/L)对苯肾上腺素(PE,10-5mol/L)预收缩的内皮完整或去内皮血管环均产生浓度依赖性的舒张作用;美皂异黄酮对高浓度氯化钾(KCl,6×10-2mol/L)预收缩的血管环也产生浓度依赖性的舒张作用;四乙胺(TEA,5×10-3mol/L)或格列苯脲(3×10-6mol/L)预处理对美皂异黄酮诱导的去内皮动脉环舒张作用具有明显的抑制效应;在无钙液中,美皂异黄酮抑制PE引起的去内皮主动脉环的短暂收缩。结论:美皂异黄酮的非内皮依赖性血管舒张作用的机制可能涉及血管平滑肌细胞的Ca2+激活K+通道和ATP敏感性K+通道的激活,以及肌浆网内钙离子释放的减少。     

香青兰总黄酮对大鼠离体胸主动脉的舒张作用

香青兰(Dracocephalum MoldavicaL.)为传统维吾尔族药材,具有补益心脑之功效,现代研究表明其对冠心病、心绞痛等病具有治疗作用。该文作者采用大鼠离体胸主动脉灌流技术,观察了香青兰总黄酮的血管舒张作用,旨在为阐明其活性物质基础和作用机制提供依据。结果表明:1)10.0～40.0mg/L香青兰总黄酮对内皮完整和去内皮大鼠主动脉环的基础张力没有明显影响。2)10.0～40.0mg/L香青兰总黄酮对去甲肾上腺素(NE,10μmol/L)所致的内皮完整和去内皮血管均有浓度依赖性的舒张作用,对内皮完整血管的舒张作用更强;一氧化氮合酶抑制剂左旋硝基精氨酸甲酯L-NAME(0.1mmol/L)、鸟苷酸环化酶抑制剂亚甲蓝(10μmol/L)和环氧合酶抑制剂吲哚美辛(10μmol/L)预处理均可一定程度上抑制香青兰总黄酮的血管舒张作用,表明血管内皮合成的一氧化氮(NO)信号通路和前列环素(PGI2)信号通路参与了香青兰总黄酮的血管舒张作用。3)香青兰总黄酮预处理去内皮血管环可以抑制细胞外钙内流所致的血管收缩,但对细胞内钙释放所致的血管收缩没有影响,香青兰总黄酮对高钾(60mmol/L KCl)所致血管收缩没有...     

胍丁胺对离体大鼠主动脉张力的影响及其受体机制

采用离体血管环灌流方法,观察了胍丁胺（agmatine,Agm)对大鼠胸主动脉张力的影响,并探讨其受体机制,实验结果如下：（1）在苯肾上腺素PE,10^-6mol/L)引起血管预收缩的 基础上,Agm(10^-7-10^-2mol/L)剂量依赖性地舒张大鼠胸主动脉。（2）上述舒张反应在去除内皮和应用NOS抑制剂N^-G-mnitro-L-arginine methyl ester(L-NAME,0.5mmol/L)后依然存在,提示Agm的舒血管作用为非内皮依赖性,并无NO的参与。（3）在高Ca^2 (3mmol/L)引起血管预收缩的基础上,Agm也可剂量依赖性地舒张大鼠主动脉。（4）预先应用α2－肾上腺素能受体（α2－adrenergic receptor,α2－AR）和咪唑啉受体（IR）阻断剂idazoxan(10^-4mol/L)则可完全阻断Agm的上述作用。（5）应用α2－AR拮抗剂yohimbine(10^-4mol/L)可部分阻断Agm对大鼠主动脉的舒张反应,以上结果表明,Agm对大鼠主动脉血管的舒张作用是由α2－AR和IR共同介导。     

CYP4A抑制剂HET0016对小鼠离体主动脉血管张力的影响

为研究CYP4A抑制剂HET0016对小鼠离体主动脉血管张力的影响,对雄性C57BL/6J小鼠进行脱臼处死后,取主动脉并剪成3~4 mm长的血管环,固定于微血管测定仪的浴槽内,分别用高钾溶液(KCl 60 mmol/L)和去氧肾上腺素(Phe 1μmol/L)进行血管功能性检测,发现二者均能让离体主动脉环产生持续性收缩;然后采用累积给药法观察1μmol/L Phe处理组、60 mmol/L高钾处理组、eNOS抑制剂L-NAME(100μmol/L)和L-钙通道阻滞剂nifedipine(1μmol/L)单独或共同孵育后Phe(1μmol/L)预收缩处理组中不同浓度HET0016对小鼠离体主动脉环张力的影响,并探讨其可能的作用机制。结果发现,高浓度的HET0016可以舒张高钾和Phe预收缩的内皮完整的主动脉环;对于L-NAME单独孵育后Phe预收缩的内皮完整的主动脉环,只有高浓度的HET0016有显著舒张作用;而对于nifedipine单独孵育以及L-NAME和nifedipine共同孵育后Phe预收缩的主动脉环,HET0016的舒张作用呈明显的浓度依赖性。这些结果显示,HET0016这种舒张作用是多通道的,呈部分的内皮依赖性,但也不是主要通过L-电压门控钙通道产生,只有在高浓度的情况下才开始影响L-电压门控钙通道。     

超氧阴离子抑制大鼠肠系膜阻力血管内皮依赖性舒张功能

目的:研究超氧阴离子对大鼠肠系膜阻力血管内皮细胞超极化因子(EDHF)和一氧化氮(NO)引起的血管舒张作用的影响及其可能机制.方法:雄性Sprague-Dawley大鼠,取肠系膜血管三级分支约2 mm长血管环,置于DMT 610 M系统,记录张力变化.血管环浴液中加入焦酚建立超氧阴离子损伤模型.结果:焦酚(10,100,300和1 000 μmol/L)可浓度依赖性地引起乙酰胆碱(ACh)诱导的肠系膜阻力血管舒张功能减弱;其中,300 μmol/L焦酚显著减弱肠系膜血管环由ACh诱导的EDHF和NO介导的内皮依赖性血管舒张效应,但对硝普钠和吡那地尔引起的内皮非依赖性的血管舒张作用无明显影响.结论:超氧阴离子可减弱阻力血管内皮依赖性舒张反应,其机制可能与超氧阴离子抑制了阻力血管内皮细胞EDHF和NO的作用有关.     

一氧化碳对大鼠离体肺动脉的舒张作用

本研究观察了一氧化碳 (CO)对离体大鼠肺动脉的舒张作用。制备Wistar大鼠肺动脉环 ,作出ACh浓度效应曲线之后 ,肺动脉环用一氧化氮合成酶抑制剂L NAME 3 0 μmol/L (n =10 )或血红素氧化酶抑制剂ZnPPIX 10μmol/L +L NAME 3 0 μmol/L (n =10 )孵育 3 0min ,再制备一个ACh的浓度效应曲线 ,观察ZnPPIX对ACh的浓度效应曲线的影响。另取一组肺动脉环 ,分为内皮完整组和去内皮组 ,观察外源性CO对肺动脉环张力的影响。结果表明 ,用L NAME孵育后 ,ACh的血管舒张反应受抑 ,最大抑制率为 5 0 4± 9 2 % ;用ZnPPIX +L NAME孵育后 ,ACh的血管舒张反应进一步受抑 ,最大抑制率为 84 4± 11 2 %。外源性CO无论对内皮完整组还是去内皮组肺动脉都有舒张作用。本研究提示 ,ZnPPIX可抑制ACh的内皮依赖性肺动脉舒张反应 ,CO是一个内皮源性的血管舒张因子 ,外源性CO可舒张肺动脉     

血管钠肽、 C型钠尿肽和心房钠尿肽舒血管作用的对比

本实验采用离体血管灌流方法,观察和比较血管钠肽（ＶＮＰ）,Ｃ型钠尿肽（ＣＮＰ）和心房钠尿肽（ＡＮＰ）对大鼠肺动脉,腹主动脉和腹腔静脉的舒张作用。．结果表明,ＶＮＰ,ＣＮＰ和ＡＮＰ对离体大鼠的保留内皮与去内皮的肺动脉,腹主动脉和腹腔静脉均有浓度依赖性舒张作用。     

Inhibition of hypoxia-induced proliferation and collagen synthesis by vasonatrin peptide in cultured rat pulmonary artery smooth muscle cells

The aim of the present research is to investigate the effects of vasonatrin peptide (VNP) on hypoxia-induced proliferation and collagen synthesis in pulmonary artery smooth muscle cells (PASMCs). Smooth muscle cells isolated from rat pulmonary artery were cultured and used at passages 3-5. Cell proliferation and collagen synthesis were evaluated by cell counts, [(3)H] thymidine and [(3)H] proline incorporation. The results showed that cells exposed to hypoxia for 24 h exhibited a significant increase in [(3)H] thymidine (93%) and [(3)H] proline (52%) incorporation followed by a significant increase in cell number (47%) at 48 h in comparison with the respective normoxic controls. VNP reduced hypoxia-stimulated increase in cell proliferation in a concentration-dependent manner from 10(-8) to 10(-6) mol/L and attenuated hypoxia-induced collagen synthesis ranging from 10(-6) to 10(-5) mol/L, which is similar to but more potent than both ANP and CNP. The action of VNP on PASMCs was mimicked by 8-bromo-cGMP (10(-4) mol/L, the membrane-permeable cGMP analog), and blocked by HS-142-1 (2 x 10(-5) mol/L), the particulate guanylyl cyclase-coupled natriuretic peptide receptor antagonist, or KT-5823 (10(-6) mol/L), the cGMP-dependent protein kinase (PKG) inhibitor. The results suggest that VNP inhibits hypoxia-stimulated proliferation and collagen synthesis in cultured rat PASMCs via particulate guanylyl cyclase-coupled receptors through cGMP/PKG dependent mechanisms.     

HS-142-1, a novel polysaccharide of microbial origin, specifically recognizes guanylyl cyclase-linked ANP receptor in rat glomeruli.

HS-142-1, a novel polysaccharide, of microbial origin had been characterized as a specific antagonist of guanylyl cyclase-linked atrial natriuretic peptide (ANP) receptors (ANP-GC receptor) in bovine adrenal cortex. The effect of HS-142-1 on ANP receptors of rat glomeruli were examined. HS-142-1 blocked rat ANP (r-ANP)-stimulated cGMP production in a concentration-dependent manner, although it caused only slight inhibition in the specific binding of [125I]-rANP to the glomeruli where only a small portion of the binding sites are coupled to guanylyl cyclase. HS-142-1 recognized the 135K ANP receptor which is thought to be ANP-GC receptors but did not recognized 60K receptor, guanylyl cyclase-free type from affinity cross-linking studies with glomerular membranes. These results indicate that HS-142-1 is a specific antagonist for the ANP-GC receptor in rat glomeruli, and that it will be a powerful tool for understanding the physiological roles of ANP in renal responses.     

HS-142-1, a novel antagonist for natriuretic peptides,has no effect on the third member of membrane bound guanylate cyclases (GC-C) in T84 cells

HS-142-1, a novel non-peptide antagonist for natriuretic peptide, exerts antagonistic actions almost equally on two similar guanylate cyclase-linked natriuretic peptide receptors (GC-A and GC-B), but has little or no effect on the binding of natriuretic peptides to a membrane protein, the so-called “clearance receptor”, which binds all natriuretic peptides. The third mammalian form of membrane bound guanylate cyclases (GC-C) was identified not as a natriuretic peptide receptor, but as a receptor for heat-stable enterotoxins (STa). In this study, we examined effects of HS-142-1 on GC-C (STaR) in T84 cells and showed that HS-142-1 exerts neither agonistic nor antagonistic activity for GC-C, indicating that HS-142-1 is not a common antagonist for a family of membrane bound guanylate cyclase receptors, but a specific antagonist for the guanylate cyclase-linked natriuretic peptide receptors.     

Vasonatrin peptide,a novel protector of dopaminergic neurons against the injuries induced by n-methyl-4-phenylpyridiniums

Vasonatrin peptide (VNP), a novel manmade natriuretic peptide, is known as a cardiovascular active substance. However, its neuroeffects are largely unknown. Here, cultured dopaminergic neurons from ventral mesencephalon of mouse were exposed to N-methyl-4-phenylpyridinium (MPP⁺), and the effects of VNP on the neurotoxicity of MPP⁺ were investigated. As a result, MPP⁺ caused injuries in the dopaminergic neurons. VNP significantly reduced the cytotoxicity of MPP⁺ by increasing axon number and length of dopaminergic neurons, and by enhancing the cell viability. Also, the MPP⁺-induced depolymerization of β-Tubulin III was attenuated by the treatment of VNP. In addition, VNP significantly increased the intracellular levels of cGMP. These effects of VNP were mimicked by 8-br-cGMP (a cell-permeable analog of cGMP), whereas inhibited by HS-142-1 (the antagonist of the particulate guanylyl cyclase-coupled natriuretic peptide receptors), or KT-5823 (a cGMP-dependent protein kinase inhibitor). Taken together, VNP attenuates the neurotoxicity of MPP⁺ via guanylyl cyclase-coupled NPR/cGMP/PKG pathway, indicating that VNP might be a new effective reagent in the treatment of neuron degeneration of dopaminergic neurons in Parkinson's disease (PD).     

Stable expression of natriuretic peptide receptors: effects of HS-142-1, a non-peptide ANP antagonist.

We established clonal cell lines stably expressing each of two subtypes of membrane bound guanylate cyclases (GC-A and GC-B), which are known as natriuretic peptide receptors. Using these cell lines, we showed that GC-A is an ANP/BNP receptor, whereas GC-B is a specific receptor for CNP. Effects of HS-142-1, a novel non-peptide ANP antagonist, on GC-A and GC-B were examined by using these cells. In cells expressing either GC-A or GC-B, HS-142-1 inhibited cGMP production elicited by ANP or CNP with IC50 values of 1.8 micrograms/ml and 1.5 micrograms/ml, respectively, and also competitively blocked specific binding of the natriuretic peptides with IC50 values of 2.2 micrograms/ml and 3.3 micrograms/ml, respectively. These results indicate that HS-142-1 is a potent antagonist of CNP as well as ANP. We also showed that CNP suppressed the growth of cells expressing GC-B by 22% and that HS-142-1 blocked the antiproliferative action of CNP.     

Mutagenicity of Isothiocyanates,Isocyanates and Thioureas on Salmonella typhimurium

During the screening program for atrial natriuretic peptide (ANP) receptor ligands of microbial origin, we isolated a novel nonpeptide ANP antagonist, HS-142-1, from a culture broth of Aureo-basidium pullulans var. melanigenum. Structural analysis showed that HS-142-1 was composed of 20–30 kinds of β-1,6-glucan esterified by caproyl groups; each component had an almost equal potency. HS-142-1 inhibited [¹²⁵I]-rANP binding to its receptor in rabbit kidney cortex membranes with an IC₅₀ of 0.3μg/ml and antagonized ANP-induced cGMP production by bovine lung membranes in a dose-dependent fashion. The discovery of this nonpeptide ANP antagonist, HS-142-1, will provide a useful tool to study the physiological significance of natriuretic peptide system.     

Inhibition of the proliferation of smooth muscle cells from human coronary bypass vessels by vasonatrin peptide

Abnormal proliferation of vascular smooth muscle cells (VSMCs) is known to be a key event in the development of atherosclerosis and restenosis. The present study examined the effect of a novel synthetic natriuretic peptide, vasonatrin peptide (VNP), on norepinephrine (NE)-induced proliferation of VSMCs from coronary bypass vessels. Human VSMCs were isolated from an internal mammary artery (IMA) and saphenous vein (SV) by explant culture and stimulated with NE. MTT assay and [3H] thymidine-incorporation were undertaken to analyze cell proliferation and radioimmunoassay was used to determine the level of intracellular cyclic 3',5'-guanosine monophosphate (cyclic GMP). NE (10(-8) - 10(-7) mol/l) had a mitogenic effect in human VSMCs from both SV and IMA. However, NE-stimulated proliferation of VSMCs from SV was greater than that from IMA. Furthermore, low concentration of NE (10(-10) mol/l) promoted cell growth in SV-derived cells but not in IMA-derived cells. VNP (10(-8) - 10(-6) mol/l) reduced NE-induced cell proliferation and increased intracellular cyclic GMP, which were abrogated by HS-142-1. In addition, the growth inhibition of VNP was mimicked by 8-bromo-cGMP. These results indicate that VNP has a significant inhibitory effect on NE-stimulated proliferation of human VSMCs from both IMA and SV, which is mediated by guanylate cyclase-linked receptors by increasing cyclic GMP.